Cellular determinants of resistance to indolocarbazole analogue 6-n-formylamino-12,13-dihydro-l,ll-dihydroxy-13(/3-d-giucopyranosyi)5//- indolo[2,3-aipha]pyrroio[3,4-c]carbazole-5,7(6//)-dione(nb-506), a novel potent topoisomerase i inhibitor, in multidrug-resistant nhuman tumor cells

Oncology Research

Volumn 9, Issue 9, 1997, Pages 485-494

  Vanhoefer, Udo ^a   Voigt, Wieland ^a   Hilger, Ralf A ^a   Yin, Ming Biao ^a   Harstrick, Andreas ^a   Seeber, Siegfried ^a   Rustum, Youcef M ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

MDRI; MRP; Multidrug resistance; NB 506; Topoisomerase 1

Indexed keywords

6 FORMYLAMINO 12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 GLUCOSIDE; ABC TRANSPORTER; CAMPTOTHECIN; CARBAZOLE DERIVATIVE; DNA TOPOISOMERASE; DOXORUBICIN; ENZYME INHIBITOR; GLUCOSIDE; GLYCOPROTEIN P; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN;

ARTICLE; CELL COUNT; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; FEMALE; FIBROSARCOMA; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; METABOLISM; MULTIDRUG RESISTANCE; NORTHERN BLOTTING; OVARY TUMOR;

ATP-BINDING CASSETTE TRANSPORTERS; BLOTTING, NORTHERN; CAMPTOTHECIN; CARBAZOLES; CELL COUNT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA TOPOISOMERASES, TYPE I; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; FIBROSARCOMA; GLUCOSIDES; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0031297095     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Hsiang, Y.-H.; Liu, L. F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 48:1722-1726; 1988.
2. Slichenmeyer, W. J.; Rowinsky, E. K.; Donehower, R. C.; Kaufmann, S. H. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst. 85:271-291; 1993.
3. Pommier, Y. Eukaryotic DNA topoisomerase I: Genome gatekeeper and its intruders, camptothecins. Semin. Oncol. 23(Suppl. 3):3-10; 1996.
4. Chen, A. Y.; Liu, L. F. DNA topoisomerases: Essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol. 34: 191-218; 1994.
5. Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58:351-375; 1989.
6. Covey, J. M.; Jaxel, C.; Kohn, K. W. ; Pommier, Y. Proteinlinked DNA breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase 1. Cancer Res. 49:50165022; 1989.
7. Tsao, Y.-P.; Russo, A.; Nyamuswa, G.; Silber, R.; Liu, L. F. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: Studies in a cell-free SV40 DNA replication system. Cancer Res. 54:5908-5914; 1994.
8. Ryan, A. J.; Squires, S.; Strutt, H. L.; Evans, A.; Johnson, R. T. Different fates of camptothecin-induced replication fork-associated double-strand breaks in mammalian cells. Carcinogenesis 15:823-828; 1994.
9. Ryan, A. J.; Squires, S.; Strutt, H. L.; Johnson, R. T. Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucleic Acids Res. 19:3295-3300; 1991.
10. Eng, W. K.; McCabe, F. L.; Tan, K. B.; Mattern, M. R.; Hofmann, G. A.; Woessner, R. D.; Hertzberg, R. P.; Johnson, R. K. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol. Pharmacol. 38:471-480; 1990.
11. Kapoor, R.; Slade, D. L.; Fujimori, A.; Pommier, Y.; Harker, W. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol. Res. 7:83-95; 1995.
12. Kanazawa, F.; Sugimoto, Y.; Minato, K.; Kasahara, K.; Bungo, M.; Nakagawa, K.; Fujiwara, Y.; Liu, L. F.; Saijo, N. Establishment of a camptothecin analogue (CPT-1 l)-resistant cell line of human non-small cell lung cancer: Characterization and mechanism of resistance. Cancer Res. 50:5919-5924; 1990.
13. Sugimoto, Y.; Tsukaharas, S.; Oh-hara, T.; Isoe, T.; Tsuruo, T. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res. 50:6925-6930; 1990.
14. Beidler, D. R.; Cheng, Y. C. Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol. Pharmacol. 47:907-914; 1995.
15. Andoh, T.; Ishii, K.; Suzuki, Y.; Ikegami, Y.; Kusunoki, Y.; Takemoto, Y.; Okada, K. Characterization of a mammalian mutant with a camptothecin resistant DNA topoisomerase I. Proc. Natl. Acad. Sei. USA 84:5565-5569; 1987.
16. Gromova, I.; Kjeldsen, E.; Svejstrup, J. Q.; Aisner, Q.; Christiansen, K.; Westergaard, O. Characterization of an altered DNA catalysis of a camptothecin-resistant eukaryotic topoisomerase I. Nucleic Acids Res. 21:593-600; 1993.
17. Benedetti, P.; Fiorani, P.; Capunani, L.; Wang, J. C. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine. Cancer Res. 53:4343-4348; 1993.
18. Tan, K. B.; Mattern, M. R.; Eng, W. K.; McCabe, F. L.; Johnson, R. K. Nonproductive rearrangement of DNA topoisomerase I and 11 genes: Correlation with resistance to topoisomerase inhibitors. J. Natl. Cancer Inst. 81:1732-1735; 1989.
19. Gupta, M.; Fujimori, A.; Pommier, Y. Eukaryotic DNA topoisomerases I. Biochim. Biophys. Acta 1262:1-14; 1995.
20. Hendricks, C. B.; Rowinsky, E. K.; Grochow, L. B.; Donehower, R. C.; Kaufmann, S. C. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res. 52:2268-2278; 1992.
21. Mattern, M. R.; Hofmann, G. A.; Polsky, R. M.; Funk, L. R.; McCabe, F. L.; Johnson, F. L. In vitro and in vivo effects of clinically important camptothecin analogues on multidrugresistant cells. Oncol. Res. 5:467-474; 1993.
22. Maliepaard, M.; Nooter, K.; Ma, J.; Loos, W. J.; Kolker, H. J.; Verweij, J.; Stoter, G.; Schellens, J. H. M. Relationship between P-glycoprotein, multidrug resistance-associated protein, and cellular accumulation of topoisomerase I inhibitors. Proc. Am. Assoc. Cancer Res. 37:312; 1996.
23. Cole, S. P. C.; Bhardwaj, G.; Gerlach, J. H.; Mackie, J. E.; Grant, C. E.; Almquist, K. C.; Stewart, A. J.; Kurz, E. U.; Duncan, A. M.; Deeley, R. G. Overexpression of a transporter gene in a multidrug-resistant human cancer cell line. Science 258:1650-1654; 1992.
24. Muller, M.; Meijer, C.; Zaman, G. J. R.; Borst, P.; Scheper, R. J.; Mulder, N. H.; de Vries, E. G. E.; Jansen, P. L. M. Overexpression of the gene encoding the multidrug resistanceassociated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc. Natl. Acad. Sei. USA 91: 13033-13037; 1994.
25. Vanhoefer, U.; Cao, S.; Minderman, H.; Toth, K.; Skenderis, B. S., II; Slovak, M. L.; Rustum, Y. M. D,L-buthionine(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors. Clin. Cancer Res. 2:1961-1968; 1996.
26. Zaman, G. J. R.; Lankelma, J.; van Tellingen, O.; Beijnen, J.; Dekker, H.; Paulusma, C.; Oude Elferink, R. P. J.; Baas, F.; Borst, P. Role of glutathione in the export of compounds from cells by the multidrug resistance-associated protein. Proc. Natl. Acad. Sei. USA 92:7690-7694; 1995.
27. Yang, C.-H. J.; Horton, J. K.; Cowan, K. H.; Schneider, E. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase 1 alterations. Cancer Res. 55:4004-4009; 1995.
28. Kawato, Y.; Aonuma, M.; Hirota, Y.; Kuga, H.; Sato, K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 51:4187-4191; 1991.
29. Yoshinari, T.; Matsumoto, M.; Arakawa, H.; Okada, H.; Noguchi, K.; Suda, H.; Okura, A.; Nishimura, S. Novel antitumor indolocarbazole compound 6-N-formyIamino-12,13dihydro-l,ll-dihydroxy-13-(0-D-glucopyranosyl)-5H-indolo[2, 3-alpha]pyrrolo[3,4-c] carbazo!e-5,7(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity. Cancer Res. 55: 1310-1315; 1995.
30. Arakawa, H.; Iguchi, T.; Morila, M.; Yoshinari, T.; Kojiri, K.; Suda, H.; Okura, A.; Nishimura, S. Novel antitumor indolocarbazole compound 6-N-formylamino-l2,13-dihydro1,11 -dihydroxy- 13-(/3-D-glucopyranosyl)-5H-indoIo-[2,3a!pha]pyrrolo[3,4-c] carbazole-5,7(6H)-dione (NB-506): Its potent antitumor activities in mice. Cancer Res. 55:13161320; 1995.
31. Kanzawa, F.; Nishio, K.; Kubota, N.; Saijo, N. Antitumor activities of a new indolocarbazole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3/NB. Cancer Res. 55:2806-2813; 1995.
32. Ohé, Y.; Tanigawara, H.; Fujii, H.; Ohtsu, T.; Wakita, H.; Igarashi, T.; Minami, H.; Eguchi, K.; Shinkai, T.; Tamura, T.; Kunitoh, H.; Saijo, N.; Okada K.; Ogino, H.; Sasaki, Y. Phase I and pharmacology study of a 5-day infusion of NB506. Proc. Am. Soc. Clin. Oncol. 16:I99a; 1997.
33. Slovak, M. L.; Ho, P. G.; Bhardwaj, J.; Kurz, E. U.; Deeley, R. G.; Cole, S. P. C. Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Cancer Res. 53:3221-3225; 1993.
34. Slovak, M. L.; Ho, J. P.; Cole, S. P. S.; Deeley, R. G.; Greenberger, L.; de Vries, E. G. E.; Broxterman, H. J.; Scheffer, G. L.; Scheper, R. J. The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: Evidence that chromosome breakage plays a key role in MRP or LRP gene amplification. Cancer Res. 55:4214-4219; 1995.
35. Minderman, H.; Vanhoefer, U.; Toth, K.; Minderman, H.; Rustum, Y. M. A unique human ovarian carcinoma cell line expressing CD34 in association with selection for multidrug resistance. Cancer 78:2427-2436; 1996.
36. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer drug screening. J. Natl. Cancer Inst. 82:1107-1112; 1990.
37. Niwa, K.; Yamada, K.; Furukawa, T.; Shudo, N.; Seto, K.; Matsumoto, T.; Takao, S.; Akiyama, S.; Shimazu, H. Effect of a dihydropyridine analogue, 2-[benzyl(phenyl)-amino]ethyl l,4-dihydro-2,6-dimethyl-5-(5,5-dimethyl-2-oxo-l,3,2-dioxa-phosphorinan-2-yl)-1- (2-morpholinoethyl)-4-(3-nitrophenyl)-3pyridinecarboxylate on reversing in vivo resistance of tumor cells to adriamycin. Cancer Res. 52:3655-3660; 1992.
38. Chomczynski, P.; Sacchi, N. Single-step method of RNA isolation by acid guanidinium (hiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159; 1987.
39. Takeda, S.; Shimazoe, T.; Sato, K.; Sugimoto, Y.; Tsuruo, T.; Kono, A. Differential expression of DNA topoisomerase I gene between CPT-11 acquired- and native-resistant human pancreatic tumor cell lines: Detected by RNA/PCR-based quantitation assay. Biochem. Biophys. Res. Commun. 184: 618-625; 1992.
40. D'Arpa, P.; Machlin, P. S.; Ratrie, H., Ill; Rothfield, N.; Cleveland, D. W.; Earnshaw, W. C. cDNA cloning of human DNA lopoisomerase I: Catalytic activity of a 67.7-kDa carboxyl-terminal fragment. Proc. Natl. Acad. Sei. USA 85: 2543-2547; 1988.
41. Deffie, A. M.; Batra, J. K.; Goldenberg, G. J. Direct correlation between DNA topoisomerase II activity and cytoloxicity in adriamycin-sensitive and resistant P388 leukemia cell lines. Cancer Res. 49:58-62; 1989.
42. Trask, D. K.; DiDonato, J. A.; Muller, M. T. Rapid detection and isolation of covalent DNA/protein complexes: Application to topoisomerase I and II. EMBOJ. 3:671-676; 1984.
43. Panadero, A.; Yin, M.-B.; Voigt, \V.; Rustum, Y. M. Contrasting patterns of DNA fragmentation induced by thymidylate synthase inhibitors, ZD1694 and AG-331. Oncol. Res. 7: 73-81; 1995.
44. Liu, L. F.; Miller, K. G. Eukaryotic DNA topoisomerases: Two forms of type I DNA topoisomerases from HeLa cell nuclei. Proc. Natl. Acad. Sei. USA 78:3487-3491; 1981.
45. Hsiang, Y.-H.; Lihou, M. G.; Liu, L. F. Arrest of replication forks by drug-stabilized topoisomerase 1-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49:5077-5082; 1989.
46. Holm, C.; Covey, J. M.; Kerrigan, D.; Pommier, Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase 1 and II inhibitors in Chinese hamster DC3F cells. Cancer Res. 49:6365-6368; 1989.